STAT+: FDA to reconsider treatment for rare cancer after its surprise rejection
The companies developing Ebvallo reached an agreement with the FDA to address its main reason for rejecting the drug.
Original Source
Read the full article at Statnews →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.